Navigation Links
Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting

miting cardiac effects as well as effects on the thyroid hormone axis, muscle metabolism and bone turnover. Metabasis believes that the combination of a TR beta-selective receptor agonist and liver-targeting could harness the efficacy of the approach by avoiding extra-hepatic activation of TR alpha receptors and TR beta receptors that may lead to these therapy-limiting side effects.

"MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol, serum triglycerides and liver fat," stated Dr. Mark Erion, executive vice president of research and development and chief scientific officer of Metabasis. "MB07811 combines a novel agonist selective for the beta isoform of the thyroid hormone receptor with our proprietary, liver-targeting HepDirect(R) prodrug technology. The combination of beta receptor selectivity, liver-targeting and other structural characteristics that limit extra-hepatic activity provides a product candidate that exhibits significant efficacy while avoiding side effects commonly associated with activation of thyroid hormone receptors outside the liver. If we can demonstrate these characteristics in humans, it should provide important evidence that MB07811 and this class of drugs could represent an exciting new therapeutic approach for treating hyperlipidemia."

Dr. Paul Laikind, president and chief executive officer of Metabasis, said, "The results of these studies and others supported the decision to initiate the clinical development of MB07811. The first human clinical study was successfully completed late last year and we expect to start a Phase 1b multiple dose study in healthy volunteers with moderately elevated LDL cholesterol by the end of this quarter."

About Metabasis (www.mbasis.com):

Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
2. Metabasis Therapeutics to Present Poster at American Association for Cancer Research
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/2/2014)... 2, 2014   Intrexon Corporation (NYSE: ... announced that it has entered into an Exclusive Channel ... of Sanofi (EURONEXT: SAN and NYSE: SNY ... specific family of its marketed Active Pharmaceutical Ingredients (APIs) ... . This collaboration will leverage Intrexon,s proprietary technology ...
(Date:9/2/2014)... Cepheid (NASDAQ: CPHD) announced today the release ... molecular test for rapid, accurate and reliable determination ... RSV infection. The test will be marketed as ... In Vitro Diagnostic Medical Devices, bringing ... Xpert Flu/RSV XC runs on Cepheid,s GeneXpert ® ...
(Date:9/2/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... today announced that the Company,s management will participate in the ... Global Healthcare Conference, to be held at the Grand Hyatt ... Morgan Stanley Asia Pacific Healthcare Day, to be held at ... Aegis Healthcare & Technology Conference, to be held at the ...
Breaking Medicine Technology:Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4Sinovac to Participate in Upcoming Investor Conferences 2
... 28, 2011 Burg Simpson Eldredge Hersh & Jardine, P.C., ... delighted to announce that shareholder, Seth. A. Katz, has been ... a member of the Plaintiffs, Steering Committee in the multidistrict litigation ... ASR XL Acetabular Hip System. In August 2010, ...
... 28, 2011 Awarepoint Corporation, a privately held ... with 91 hospital sites contracted consisting of 45,062,013 ... network coverage in U.S. hospitals and 135,265 healthcare ... enterprise-wide U.S. hospital client base for RTLS in ...
Cached Medicine Technology:Burg Simpson Leads National Litigation Against DePuy Orthopaedics, Inc. 2Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 2Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 3Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 4
(Date:9/2/2014)... key to more youthful immune function might already be ... the Journal of Leukocyte Biology ... mice had different responses to Mycobacterium tuberculosis ... reversed by ibuprofen. , "Inflammation in old age can ... Ph.D., a researcher involved in the work from the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 2014 Nanomedicine is essentially based ... treating and/or prevention of diseases and infections. Nanotechnology-based ... neurological, and oncology diseases. , Nanomedicine is ... various nanoparticles, their medical usages, and their actions ... scope for research in this domain, and scientists ...
(Date:9/2/2014)... September 02, 2014 On Saturday, September 6, ... and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. ... for better health and wellness for people of all ages ... to the public, will be held at Kiest Park Recreation ... to 1:00 pm. , “Since 2007, we have partnered ...
(Date:9/2/2014)... Durable Medical Goods manufacture ThermoTek , announced ... company LeaseQ, Inc. to help customers acquire capital goods ... LeaseQ’s breakthrough finance shopping platform has enabled businesses to ... run their business. , Said LeaseQ Vice President ... sales team to provide customers faster access to capital ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2
... have found out the benefits of oral ZYVOX for ... bacterial infections. They compared data from 80 health care ... of Intravenous Vancomycin. The results show that oral tablets ... of money spent to health clinics compared to vancomycin. ...
... from Children’s Hospital of Boston have reconstructed defective ... researchers used amniotic fluid for growing the sections ... living tissues into lambs, while they were in ... used for altering birth defects. Undifferentiated stem cell ...
... a life of dignity with access to medicines and care ... cancer, say experts on the eve of World Hospice and ... states like Kerala, Maharashtra, Karnataka and Orissa as well as ... administer strong pain killers that make life more bearable., ...
... is calling for concerted action following the recent release ... (WHO). // ,"Preventing Chronic Diseases: A ... global burden of chronic diseases including cardiovascular disease, cancer, ... global action to prevent chronic disease could save the ...
... total abdominal hysterectomy and laparoscopically assisted vaginal hysterectomy ... the advantages of lower morbidity // and faster ... vaginal route, although there is a high feasibility ... gynecologists need to be familiar with surgical techniques. ...
... and obstructive sleep apnea share some common symptoms, due to ... diagnosis. Obstructive sleep apnea (OSA) occurs when the tongue or ... the airway. This can happen more than 50 times an ... last as long as 60 seconds. The problem is twice ...
Cached Medicine News:Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2Health News:Terminally Ill deserves a better quality of Life 2Health News:Terminally Ill deserves a better quality of Life 3Health News:Reversibility of symptoms of depression using CPAP in patients with obstructive sleep apnea 2
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
... is a new, portable, light weight, high ... dermatology, cosmetic and plastic surgery, general surgery, ... skin resurfacing, it is the smallest, yet ... the market. It provides an ideal treatment ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs sophisticated Ceralas D15/810 diode laser is ... ideal for many soft tissue applications. With ... D15/810 features a flexible fiber optic delivery ... irrigated or dry environments alike.,Compact and portable, ...
Medicine Products: